Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Sees Significant Decline in Short Interest

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 200 shares, a drop of 86.7% from the October 15th total of 1,500 shares. Based on an average daily trading volume, of 2,300 shares, the days-to-cover ratio is currently 0.1 days.

Clinuvel Pharmaceuticals Stock Performance

OTCMKTS:CLVLY remained flat at $8.94 during trading hours on Tuesday. 702 shares of the company’s stock were exchanged, compared to its average volume of 2,724. Clinuvel Pharmaceuticals has a 52 week low of $8.42 and a 52 week high of $12.06. The stock has a fifty day moving average of $9.59 and a 200-day moving average of $9.77.

Clinuvel Pharmaceuticals Increases Dividend

The company also recently declared a dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a dividend of $0.0299 per share. This is a boost from Clinuvel Pharmaceuticals’s previous dividend of $0.03. The ex-dividend date of this dividend was Monday, September 9th.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).